Celnovte Biotech specializes in the research, development, manufacturing, and distribution of advanced pathological diagnostic reagents and instruments. Our market-leading portfolio includes IHC, CISH, and FISH products, designed to meet the highest standards of sensitivity and specificity.
- Primary Antibody: 120+ Self-cloned MMab and RMab primary antibodies and 30 of them won optimal NordiQC assessment. 500+ Ready to use.
- MicroStacker™ IHC Detection System: Renowned for its unsurpassed sensitivity and specificity.
- PolyStacker™ Technology: Reduces turnaround time of frozen section IHC experiments to as short as 10 minutes.
- SuperISH™ RNA In-Situ Hybridization Technology: Enables detection of RNA targets at the single molecular level and single-cell resolution.
- Automated Instrumentation: Including IHC slide stainers, H&E stainers, special stainers, cytopathology instruments, and digital slide scanners. Since 2018, we have successfully installed over 700 units of fully automated IHC stainers globally.
Founded in 2010, Celnovte is headquartered in Rockville, MD for reagent and instrument development. It also has subsidiaries in Shenzhen for instrument R&D, in Suzhou for research-use product development, and in Zhengzhou, China for manufacturing. Our facilities in USA and China are NMPA & GMP compliant and are certified for ISO13485, ISO9001, FDA and CE IVDR. Nowadays, Celnovte has established an extensive domestic and international pathological network, reaching over 2300+ top hospitals in China and over 40+ countries worldwide.
Our mission is to elevate precision in cancer diagnostics and enrich patients' lives through innovative products and services. We aim to be a global leader in delivering top-quality diagnostic services by prioritizing product quality, unmatched customer satisfaction, advancing scientific innovation, and building a premier organization committed to make better, do better, and be better for our customers, employees, partners, and the patient worldwide.